

Parinitha Balaji*, Sydney Munion*, Stephanie Hung, Alisha Joseph, Raelle Tiong, Joleen Wong, Jolena Phat, Sarah Lai

INTRODUCTION


Cerebroatrophic hyperammonemia, also known as Rett Syndrome or RTT, is an intricate and extremely rare neurodevelopmental disorder caused by a mutation on the methyl CpG binding protein 2 (MeCP2) gene. The MeCP2 protein is vital to the regulation of gene activity and the depth of synaptic connections between neurons. Thus, a mutation in the gene that codes for the MeCP2 protein would result in a disorder that impairs nearly every aspect of life, predominantly in young girls.

OBJECTIVE

Current treatment for RTT can only improve patients' quality of life as there is no known cure for the disorder. Therefore, we conducted a comprehensive review of the existing studies and articles published on RTT to help the scientific community gain insight into important patterns and nuances in RTT research as well as aid in the development of novel treatments for RTT patients.

METHODS

The database Web of Science was used to find the best academic articles on RTT. Once all desired articles were identified with the search term "Rett Syndrome", the top 200 most-cited articles were exported. These 200 articles were further manually reviewed to finalize a total of the top 100 articles on RTT. Inclusion criteria included: relevancy to RTT and no. of citations. The finalized 100 articles were selected for this bibliometric analysis study.




RESULTS & DISCUSSION

Publication years of the top RTT articles ranged from 1986 to 2016, with the United States being the largest contributing country. Baylor College of Medicine (TX) was the institution that contributed the largest amount of RTT articles. First authors Amir RE, Moretti P, and Hagberg B published the most-cited literature of this study. The 100 articles of this study covered a wide variety of themes from “Neuroscience & Neurology” to “Biochemistry & Molecular Biology”, with “Genetics & Heredity” being the most published theme of interest. Frequencies of the keywords “mouse model”, “DNA methylation”, “histone deacetylase” and “mecp2” have increased dramatically over the decades, suggesting that these topics have received more attention in recent years. Within these top keywords, “mouse model” and “DNA methylation” are the largest common ideas (mouse models are specimens used to study patterns & mechanisms of human disease and to test for RTT treatments, while DNA methylation is an epigenetic mark pivotal for understanding the genetics behind RTT). These keywords signal a shift in the focus of research on RTT, indicating that researchers are now looking at the causes of the disorder, and using these findings to develop potential cures.

CONCLUSION

Based on the results of our network & bibliometric analyses, we conclude that research in RTT will continue to be of interest in the upcoming years, as researchers increasingly study the genetic basis and origins of disease (MeCPG-2). The latest RTT research heavily relies on mouse models, signifying a better understanding of RTT's mechanisms in patients. This new knowledge will be used to develop potential cures for the disorder and in the near future, will change the lives of young girls and boys struggling with RTT.



THINK NEURO 2023 SUMMER RESEARCH

BIBLIOMETRIC ANALYSIS OF THE TOP 100 ARTICLES ON RETT SYNDROME:

RESEARCH IS INCREASINGLY FOCUSING ON THE EFFECTS OF THE
MUTATED MECPG2 GENE ON RETT GROWTH AND DEVELOPMENT

Parinitha Balaji*, Sydney Munion*, Stephanie Hung, Alisha Joseph, Raelle Tiong, Joleen Wong, Jolena Phat, Sarah Lai

REFERENCES

Amir, Ruthie E., Ignatia B. Van Den Veyver, Rebecca Schultz, et al. “Influence of Mutation Type and X Chromosome Inactivation on Rett Syndrome Phenotypes.” *Annals of Neurology*, vol. 47, no. 5, May 2000, pp. 670–79. DOI.org (Crossref), [https://doi.org/10.1002/1531-8249\(200005\)47:5<670::AID-ANA20>3.0.CO;2-F](https://doi.org/10.1002/1531-8249(200005)47:5<670::AID-ANA20>3.0.CO;2-F).

Amir, Ruthie E., Ignatia B. Van Den Veyver, Mimi Wan, et al. “Rett Syndrome Is Caused by Mutations in X-Linked MECP2, Encoding Methyl-CpG-Binding Protein 2.” *Nature Genetics*, vol. 23, no. 2, Oct. 1999, pp. 185–88. DOI.org (Crossref), <https://doi.org/10.1038/13810>.

Armstrong, Dawna, et al. “Selective Dendritic Alterations in the Cortex of Rett Syndrome.” *Journal of Neuropathology and Experimental Neurology*, vol. 54, no. 2, Mar. 1995, pp. 195–201. DOI.org (Crossref), <https://doi.org/10.1097/00005072-199503000-00006>.

Autry, Anita E., and Lisa M. Monteggia. “Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders.” *Pharmacological Reviews*, edited by Lynette C. Daws, vol. 64, no. 2, Apr. 2012, pp. 238–58. [pharmrev.aspetjournals.org](https://doi.org/10.1124/pr.111.005108), <https://doi.org/10.1124/pr.111.005108>.

Ballas, Nurit, et al. “Non–Cell Autonomous Influence of MeCP2-Deficient Glia on Neuronal Dendritic Morphology.” *Nature Neuroscience*, vol. 12, no. 3, Mar. 2009, pp. 311–17. [www.nature.com](https://doi.org/10.1038/nn.2275), <https://doi.org/10.1038/nn.2275>.

Bienvenu, T. “MECP2 Mutations Account for Most Cases of Typical Forms of Rett Syndrome.” *Human Molecular Genetics*, vol. 9, no. 9, May 2000, pp. 1377–84. DOI.org (Crossref), <https://doi.org/10.1093/hmg/9.9.1377>.

Bienvenu, Thierry, and Jamel Chelly. “Molecular Genetics of Rett Syndrome: When DNA Methylation Goes Unrecognized.” *Nature Reviews Genetics*, vol. 7, no. 6, June 2006, pp. 415–26. [www.nature.com](https://doi.org/10.1038/nrg1878), <https://doi.org/10.1038/nrg1878>.

Chahrour, Maria, et al. “MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription.” *Science*, vol. 320, no. 5880, May 2008, pp. 1224–29. DOI.org (Crossref), <https://doi.org/10.1126/science.1153252>.

Chao, Hsiao-Tuan, et al. “Dysfunction in GABA Signalling Mediates Autism-like Stereotypes and Rett Syndrome Phenotypes.” *Nature*, vol. 468, no. 7321, Nov. 2010, pp. 263–69. [www.nature.com](https://doi.org/10.1038/nature09582), <https://doi.org/10.1038/nature09582>.

Cheadle, J. P. “Long-Read Sequence Analysis of the MECP2 Gene in Rett Syndrome Patients: Correlation of Disease Severity with Mutation Type and Location.” *Human Molecular Genetics*, vol. 9, no. 7, Apr. 2000, pp. 1119–29. DOI.org (Crossref), <https://doi.org/10.1093/hmg/9.7.1119>.

Chen, Richard Z., et al. “Deficiency of Methyl-CpG Binding Protein-2 in CNS Neurons Results in a Rett-like Phenotype in Mice.” *Nature Genetics*, vol. 27, no. 3, Mar. 2001, pp. 327–31. [www.nature.com](https://doi.org/10.1038/85906), <https://doi.org/10.1038/85906>.

Chen, Wen G., et al. “Derepression of BDNF Transcription Involves Calcium-Dependent Phosphorylation of MeCP2.” *Science*, vol. 302, no. 5646, Oct. 2003, pp. 885–89. DOI.org (Crossref), <https://doi.org/10.1126/science.1086446>.

Cheung, Aaron Y. L., et al. “Isolation of MECP2-Null Rett Syndrome Patient hiPS Cells and Isogenic Controls through X-Chromosome Inactivation.” *Human Molecular Genetics*, vol. 20, no. 11, June 2011, pp. 2103–15. DOI.org (Crossref), <https://doi.org/10.1093/hmg/ddr093>.

Cohen, David, et al. “Specific Genetic Disorders and Autism: Clinical Contribution Towards Their Identification.” *Journal of Autism and Developmental Disorders*, vol. 35, no. 1, Feb. 2005, pp. 103–16. Springer Link, <https://doi.org/10.1007/s10803-004-1038-2>.

Couvert, P. “MECP2 Is Highly Mutated in X-Linked Mental Retardation.” *Human Molecular Genetics*, vol. 10, no. 9, Apr. 2001, pp. 941–46. DOI.org (Crossref), <https://doi.org/10.1093/hmg/10.9.941>.

Cuddapah, Vishnu Anand, et al. “Methyl-CpG-Binding Protein 2 (MECP2) Mutation Type Is Associated with Disease Severity in Rett Syndrome.” *Journal of Medical Genetics*, vol. 51, no. 3, Mar. 2014, pp. 152–58. [jmg.bmj.com](https://doi.org/10.1136/jmedgenet-2013-102113), <https://doi.org/10.1136/jmedgenet-2013-102113>.

Dani, Vardhan S., et al. “Reduced Cortical Activity Due to a Shift in the Balance between Excitation and Inhibition in a Mouse Model of Rett Syndrome.” *Proceedings of the National Academy of Sciences*, vol. 102, no. 35, Aug. 2005, pp. 12560–65. DOI.org (Crossref), <https://doi.org/10.1073/pnas.0506071102>.

Deogracias, Rubén, et al. “Fingolimod, a Sphingosine-1 Phosphate Receptor Modulator, Increases BDNF Levels and Improves Symptoms of a Mouse Model of Rett Syndrome.” *Proceedings of the National Academy of Sciences*, vol. 109, no. 35, Aug. 2012, pp. 14230–35. DOI.org (Crossref), <https://doi.org/10.1073/pnas.1206093109>.

Derecki, Noël C., et al. “Wild-Type Microglia Arrest Pathology in a Mouse Model of Rett Syndrome.” *Nature*, vol. 484, no. 7392, Apr. 2012, pp. 105–09. [www.nature.com](https://doi.org/10.1038/nature10907), <https://doi.org/10.1038/nature10907>.

Gabel, Harrison W., et al. “Disruption of DNA-Methylation-Dependent Long Gene Repression in Rett Syndrome.” *Nature*, vol. 522, no. 7554, June 2015, pp. 89–93. [www.nature.com](https://doi.org/10.1038/nature14319), <https://doi.org/10.1038/nature14319>.

Giacometti, Emanuela, et al. “Partial Rescue of MeCP2 Deficiency by Postnatal Activation of MeCP2.” *Proceedings of the National Academy of Sciences*, vol. 104, no. 6, Feb. 2007, pp. 1931–36. DOI.org (Crossref), <https://doi.org/10.1073/pnas.0610593104>.

Guy, Jacky, Brian Hendrich, et al. “A Mouse Mecp2-Null Mutation Causes Neurological Symptoms That Mimic Rett Syndrome.” *Nature Genetics*, vol. 27, no. 3, Mar. 2001, pp. 322–26. [www.nature.com](https://doi.org/10.1038/85899), <https://doi.org/10.1038/85899>.

Mnatzakanian, Gevork N., et al. “A Previously Unidentified MECP2 Open Reading Frame Defines a New Protein Isoform Relevant to Rett Syndrome.” *Nature Genetics*, vol. 36, no. 4, Apr. 2004, pp. 339–41. [www.nature.com](https://doi.org/10.1038/ng1327), <https://doi.org/10.1038/ng1327>.

Moretti, Paolo, et al. “Learning and Memory and Synaptic Plasticity Are Impaired in a Mouse Model of Rett Syndrome.” *Journal of Neuroscience*, vol. 26, no. 1, Jan. 2006, pp. 319–27. [www.jneurosci.org](https://doi.org/10.1523/JNEUROSCI.2623-05.2006), <https://doi.org/10.1523/JNEUROSCI.2623-05.2006>.

Muotri, Alysson R., et al. “L1 Retrotransposition in Neurons Is Modulated by MeCP2.” *Nature*, vol. 468, no. 7322, Nov. 2010, pp. 443–46. [www.nature.com](https://doi.org/10.1038/nature09544), <https://doi.org/10.1038/nature09544>.

Neul, J. L., et al. “Specific Mutations in Methyl-CpG-Binding Protein 2 Confer Different Severity in Rett Syndrome.” *Neurology*, vol. 70, no. 16, Apr. 2008, pp. 1313–21. [n.neurology.org](https://doi.org/10.1212/01.wnl.0000291011.54508.aa), <https://doi.org/10.1212/01.wnl.0000291011.54508.aa>.

Ramocki, Melissa B., Sarika U. Peters, et al. “Autism and Other Neuropsychiatric Symptoms Are Prevalent in Individuals with MeCP2 Duplication Syndrome.” *Annals of Neurology*, vol. 66, no. 6, Dec. 2009, pp. 771–82. DOI.org (Crossref), <https://doi.org/10.1002/ana.21715>.

Ramocki, Melissa B., Y. Jane Tavyev, et al. “The MECP2 Duplication Syndrome.” *American Journal of Medical Genetics Part A*, vol. 152A, no. 5, May 2010, pp. 1079–88. DOI.org (Crossref), <https://doi.org/10.1002/ajmg.a.33184>.

Rossignol, Daniel A., and Richard E. Frye. “Melatonin in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis: Review.” *Developmental Medicine & Child Neurology*, vol. 53, no. 9, Sept. 2011, pp. 783–92. DOI.org (Crossref), <https://doi.org/10.1111/j.1469-8749.2011.03980.x>.

Rutter, M. “Incidence of Autism Spectrum Disorders: Changes over Time and Their Meaning*.” *Acta Paediatrica*, vol. 94, no. 1, Jan. 2005, pp. 2–15. DOI.org (Crossref), <https://doi.org/10.1080/08035250410023124>.

Scala, E., et al. “CDKL5/STK9 Is Mutated in Rett Syndrome Variant with Infantile Spasms.” *Journal of Medical Genetics*, vol. 42, no. 2, Feb. 2005, pp. 103–07. [jmg.bmj.com](https://doi.org/10.1136/jmg.2004.026237), <https://doi.org/10.1136/jmg.2004.026237>.

Shahbazzian, M. D. “Insight into Rett Syndrome: MeCP2 Levels Display Tissue- and Cell-Specific Differences and Correlate with Neuronal Maturation.” *Human Molecular Genetics*, vol. 11, no. 2, Jan. 2002, pp. 115–24. DOI.org (Crossref), <https://doi.org/10.1093/hmg/11.2.115>.

Szulwach, Keith E., et al. “5-hmC–Mediated Epigenetic Dynamics during Postnatal Neurodevelopment and Aging.” *Nature Neuroscience*, vol. 14, no. 12, Dec. 2011, pp. 1607–16. [www.nature.com](https://doi.org/10.1038/nn.2959), <https://doi.org/10.1038/nn.2959>.

Tropea, Daniela, et al. “Partial Reversal of Rett Syndrome-like Symptoms in MeCP2 Mutant Mice.” *Proceedings of the National Academy of Sciences*, vol. 106, no. 6, Feb. 2009, pp. 2029–34. DOI.org (Crossref), <https://doi.org/10.1073/pnas.0812394106>.

Tsankova, Nadia, et al. “Epigenetic Regulation in Psychiatric Disorders.” *Nature Reviews Neuroscience*, vol. 8, no. 5, May 2007, pp. 355–67. [www.nature.com](https://doi.org/10.1038/nrn2132), <https://doi.org/10.1038/nrn2132>.

Tudor, Matthew, et al. “Transcriptional Profiling of a Mouse Model for Rett Syndrome Reveals Subtle Transcriptional Changes in the Brain.” *Proceedings of the National Academy of Sciences*, vol. 99, no. 24, Nov. 2002, pp. 15536–41. DOI.org (Crossref), <https://doi.org/10.1073/pnas.242566899>.

Van Esch, H., Bauters, M., Ignatius, J., Jansen, M., Raynaud, M., Hollanders, K., Lugtenberg, D., Bienvenu, T., Jensen, L. R., Géczy, J., Moraine, C., Marynen, P., Fryns, J.-P., & Froyen, G. (2005). Duplication of the MECP2 Region Is a Frequent Cause of Severe Mental Retardation and Progressive Neurological Symptoms in Males. In *The American Journal of Human Genetics* (Vol. 77, Issue 3, pp. 442–453). Elsevier BV. <https://doi.org/10.1086/444549>

Viemari, Jean-Charles, et al. “Mecp2 Deficiency Disrupts Norepinephrine and Respiratory Systems in Mice.” *Journal of Neuroscience*, vol. 25, no. 50, Dec. 2005, pp. 11521–30. [www.jneurosci.org](https://doi.org/10.1523/JNEUROSCI.4373-05.2005), <https://doi.org/10.1523/JNEUROSCI.4373-05.2005>.

Yasui, Dag H., et al. “Integrated Epigenomic Analyses of Neuronal MeCP2 Reveal a Role for Long-Range Interaction with Active Genes.” *Proceedings of the National Academy of Sciences*, vol. 104, no. 49, Dec. 2007, pp. 19416–21. DOI.org (Crossref), <https://doi.org/10.1073/pnas.0707442104>.

<https://academic.oup.com/hmg/article/13/21/2679/587458/Mild-overexpression-of-MeCP2-causes-a-progressive>. Accessed 25 July 2023.

Zhou, Y., Kaiser, T., Monteiro, P., Zhang, X., Van der Goes, Marie. S., Wang, D., Barak, B., Zeng, M., Li, C., Lu, C., Wells, M., Amaya, A., Nguyen, S., Lewis, M., Sanjana, N., Zhou, Y., Zhang, M., Zhang, F., Fu, Z., & Feng, G. (2016). Mice with Shank3 Mutations Associated with ASD and Schizophrenia Display Both Shared and Distinct Defects. In *Neuron* (Vol. 89, Issue 1, pp. 147–162). Elsevier BV. <https://doi.org/10.1016/j.neuron.2015.11.023>

Zhou, Z., Hong, E. J., Cohen, S., Zhao, W., Ho, H. H., Schmidt, L., Chen, W. G., Lin, Y., Savner, E., Griffith, E. C., Hu, L., Steen, J. A. J., Weitz, C. J., & Greenberg, M. E. (2006). Brain-Specific Phosphorylation of MeCP2 Regulates Activity-Dependent Bdnf Transcription, Dendritic Growth, and Spine Maturation. In *Neuron* (Vol. 52, Issue

Guy, Jacky, Jian Gan, et al. “Reversal of Neurological Defects in a Mouse Model of Rett Syndrome.” *Science*, vol. 315, no. 5815, Feb. 2007, pp. 1143–47. DOI.org (Crossref), <https://doi.org/10.1126/science.1138389>.

Guy, Jacky, Hélène Cheval, et al. “The Role of MeCP2 in the Brain.” *Annual Review of Cell and Developmental Biology*, vol. 27, no. 1, Nov. 2011, pp. 631–52. DOI.org (Crossref), <https://doi.org/10.1146/annurev-cellbio-092910-154121>.

Hagberg, Bengt. “Clinical Manifestations and Stages of Rett Syndrome.” *Mental Retardation and Developmental Disabilities Research Reviews*, vol. 8, no. 2, 2002, pp. 61–65. DOI.org (Crossref), <https://doi.org/10.1002/mrdd.10020>.

Helsmoortel, Céline, et al. “A SWI/SNF-Related Autism Syndrome Caused by de Novo Mutations in ADNP.” *Nature Genetics*, vol. 46, no. 4, Apr. 2014, pp. 380–84. [www.nature.com](https://doi.org/10.1038/ng.2899), <https://doi.org/10.1038/ng.2899>.

Horike, Shin-ichi, et al. “Loss of Silent-Chromatin Looping and Impaired Imprinting of DLX5 in Rett Syndrome.” *Nature Genetics*, vol. 37, no. 1, Jan. 2005, pp. 31–40. [www.nature.com](https://doi.org/10.1038/ng1491), <https://doi.org/10.1038/ng1491>.

Im, Heh-In, et al. “MeCP2 Controls BDNF Expression and Cocaine Intake through Homeostatic Interactions with microRNA-212.” *Nature Neuroscience*, vol. 13, no. 9, Sept. 2010, pp. 1120–27. [www.nature.com](https://doi.org/10.1038/nn.2615), <https://doi.org/10.1038/nn.2615>.

Issler, Orna, and Alon Chen. “Determining the Role of microRNAs in Psychiatric Disorders.” *Nature Reviews Neuroscience*, vol. 16, no. 4, Apr. 2015, pp. 201–12. [www.nature.com](https://doi.org/10.1038/nrn3879), <https://doi.org/10.1038/nrn3879>.

Jaenisch, Rudolf, and Adrian Bird. “Epigenetic Regulation of Gene Expression: How the Genome Integrates Intrinsic and Environmental Signals.” *Nature Genetics*, vol. 33, no. 3, Mar. 2003, pp. 245–54. [www.nature.com](https://doi.org/10.1038/ng1089), <https://doi.org/10.1038/ng1089>.

Jeffrey L. Neul, et al. “Rett Syndrome: Revised Diagnostic Criteria and Nomenclature.” *Annals of Neurology*, vol. 68, no. 6, Dec. 2010, pp. 944–50. DOI.org (Crossref), <https://doi.org/10.1002/ana.22124>.

Kaufmann, W. E. “Dendritic Anomalies in Disorders Associated with Mental Retardation.” *Cerebral Cortex*, vol. 10, no. 10, Oct. 2000, pp. 981–91. DOI.org (Crossref), <https://doi.org/10.1093/cercor/10.10.981>.

Kriaucionis, S. “The Major Form of MeCP2 Has a Novel N-Terminus Generated by Alternative Splicing.” *Nucleic Acids Research*, vol. 32, no. 5, Mar. 2004, pp. 1818–23. DOI.org (Crossref), <https://doi.org/10.1093/nar/gkh349>.

Lioy, Daniel T., et al. “A Role for Glia in the Progression of Rett’s Syndrome.” *Nature*, vol. 475, no. 7357, July 2011, pp. 497–500. [www.nature.com](https://doi.org/10.1038/nature10214), <https://doi.org/10.1038/nature10214>.

Liu, Zhen, et al. “Autism-like Behaviours and Germline Transmission in Transgenic Monkeys Overexpressing MeCP2.” *Nature*, vol. 530, no. 7588, Feb. 2016, pp. 98–102. [www.nature.com](https://doi.org/10.1038/nature16533), <https://doi.org/10.1038/nature16533>.

Luikenhuis, Sandra, et al. “Expression of MeCP2 in Postmitotic Neurons Rescues Rett Syndrome in Mice.” *Proceedings of the National Academy of Sciences*, vol. 101, no. 16, Apr. 2004, pp. 6033–38. DOI.org (Crossref), <https://doi.org/10.1073/pnas.0401626101>.

Lyst, Matthew J., et al. “Rett Syndrome Mutations Abolish the Interaction of MeCP2 with the NCoR/SMRT Co-Repressor.” *Nature Neuroscience*, vol. 16, no. 7, July 2013, pp. 898–902. [www.nature.com](https://doi.org/10.1038/nn.3434), <https://doi.org/10.1038/nn.3434>.

Lyst, Matthew J., and Adrian Bird. “Rett Syndrome: A Complex Disorder with Simple Roots.” *Nature Reviews Genetics*, vol. 16, no. 5, May 2015, pp. 261–75. [www.nature.com](https://doi.org/10.1038/nrg3897), <https://doi.org/10.1038/nrg3897>.

Maezawa, Izumi, et al. “Rett Syndrome Astrocytes Are Abnormal and Spread MeCP2 Deficiency through Gap Junctions.” *Journal of Neuroscience*, vol. 29, no. 16, Apr. 2009, pp. 5051–61. [www.jneurosci.org](https://doi.org/10.1523/JNEUROSCI.0324-09.2009), <https://doi.org/10.1523/JNEUROSCI.0324-09.2009>.

Maezawa, Izumi, and Lee-Way Jin. “Rett Syndrome Microglia Damage Dendrites and Synapses by the Elevated Release of Glutamate.” *Journal of Neuroscience*, vol. 30, no. 15, Apr. 2010, pp. 5346–56. [www.jneurosci.org](https://doi.org/10.1523/JNEUROSCI.5966-09.2010), <https://doi.org/10.1523/JNEUROSCI.5966-09.2010>.

Mann, J., et al. “Regulation of Myofibroblast Transdifferentiation by DNA Methylation and MeCP2: Implications for Wound Healing and Fibrogenesis.” *Cell Death & Differentiation*, vol. 14, no. 2, Feb. 2007, pp. 275–85. [www.nature.com](https://doi.org/10.1038/sj.cdd.4401979), <https://doi.org/10.1038/sj.cdd.4401979>.

Marín, Oscar. “Interneuron Dysfunction in Psychiatric Disorders.” *Nature Reviews Neuroscience*, vol. 13, no. 2, Feb. 2012, pp. 107–20. [www.nature.com](https://doi.org/10.1038/nrn3155), <https://doi.org/10.1038/nrn3155>.

Martinovich, Keri, et al. “DNA Methylation-Related Chromatin Remodeling in Activity-Dependent Bdnf Gene Regulation.” *Science*, vol. 302, no. 5646, Oct. 2003, pp. 890–93. DOI.org (Crossref), <https://doi.org/10.1126/science.1090842>.

Maunakea, Alike K., et al. “Intragenic DNA Methylation Modulates Alternative Splicing by Recruiting MeCP2 to Promote Exon Recognition.” *Cell Research*, vol. 23, no. 11,